Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + capecitabine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
fluorouracil + capecitabine is a combination chemotherapy regimen consisting of two fluoropyrimidine antimetabolites. Fluorouracil (5-FU) is a well-established antineoplastic agent that inhibits DNA synthesis by interfering with thymidylate synthase (TS), while capecitabine is an orally administered prodrug that is enzymatically converted to 5-FU within tumor tissue. This combination is frequently utilized as a backbone chemotherapy in clinical trials, such as the EORTC INNOVATION trial, for the treatment of HER2-positive resectable gastric and gastroesophageal junction (GEJ) adenocarcinomas. By targeting thymidylate synthase and incorporating into RNA and DNA, these agents disrupt tumor cell growth and replication in rapidly dividing cancer cells.
- Brand names
- XelodaAdrucilEfudex
- Other names
- 5-fluorouracil + capecitabinefluorouracil + capecitabine
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + capecitabine.